‌Blood Cancers & Blood Disorders

Blood Cancer & Blood Disorders

Peter Forsberg, MD

SCRI at Colorado Blood Cancer Institute, will present “Optec/Optal: A Phase 2 Study to Evaluate Outpatient, Step-Up Administration of Teclistamab or Talquetamab with Prophylactic Tocilizumab in Patients with Relapsed/Refractory Multiple Myeloma” in an oral presentation on Sunday, May 31 at 9:51 a.m. CDT during the session, Hematologic Malignancies—Plasma Cell Dyscrasia in E450a.

Click here to learn more about Dr. Forsberg.